Skip to content
User

Arbiter Partners Capital Management RNA trades

Paul Isaac

Paul Isaac Atrium Therapeutics, Inc stake

total: 302

Trades details

Total transactions:
3
New positions:
1
Added:
1
Reduced:
1
Held since:
2026 Q1
Held for:
3 quarters
Latest activity:
2026 Q3
According to 2026 Q3 report, Paul Isaac holds 311,719 Atrium Therapeutics, Inc (RNA) shares with a market value of roughly $2.58M accounting for 1.14% of the overall portfolio. To date, the estimated cost basis is nearly $13.42 for "buy" trades and estimated average "sell" price is $8.28. Arbiter Partners Capital Management first purchased RNA in 2026 Q1, initially acquiring 230,000 shares. Since the initial investment in Atrium Therapeutics, Inc (RNA), Arbiter Partners Capital Management has made 2 more transactions.

How many RNA shares does Paul Isaac currently hold?

According to 2026 Q3 report, Paul Isaac holds 311,719 shares of Atrium Therapeutics, Inc (RNA), valued at around $2.58M.

When did Paul Isaac buy Atrium Therapeutics, Inc (RNA)?

Paul Isaac first invested in Atrium Therapeutics, Inc (RNA) in 2026 Q1 at the reported quarter-end price of $13.37 per share.

What's the cost basis of Arbiter Partners Capital Management's RNA stake?

The estimated cost basis for Atrium Therapeutics, Inc (RNA) stake is around $13.42 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$13.42
Weighted AVG sell price:
$8.28

Paul Isaac's historical trades in Atrium Therapeutics, Inc

3 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q3
1.14%
311,719
$8.28
$2,581,033
-40.35% (-210,857)
-0.48%
2026 Q2
1.91%
522,576
$13.45
$7,028,648
+127.21% (+292,576)
+1.07%
2026 Q1
2.09%
230,000
$13.37
$3,075,100
new
+2.09%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.